Fukayama S, Bosma T J, Goad D L, Voelkel E F, Tashjian A H
Laboratory of Toxicology, Harvard School of Public Health, Boston, Massachusetts 02115.
Endocrinology. 1988 Dec;123(6):2841-8. doi: 10.1210/endo-123-6-2841.
Human PTH-related protein (hPTHrP) has been characterized as a product of tumor cells with sequence homology to the biologically active amino-terminal portion of human PTH (hPTH). We measured the relative activities of synthetic amino-terminal sequences of hPTH-(1-34) and hPTHrP-(1-34) to stimulate production of cAMP in intact human SaOS-2 osteosarcoma cells. Both peptides enhanced cAMP production at concentrations of 2.5-7.5 X 10(-10) M, had parallel dose-response curves, and were of essentially equal potency. Preincubation of SaOS-2 cells with hPTH-(1-34) or hPTHrP-(1-34) for 1 or 4 h induced homologous desensitization to a second challenge with the same peptide as well as heterologous desensitization to the other PTH peptide, but had little or no effect on the action of vasoactive intestinal peptide; the magnitudes of homologous and heterologous desensitization induced by the same doses of hPTHrP-(1-34) or hPTH-(1-34) were similar. Bone resorption-stimulating activity was measured using 40Ca2+ release from neonatal mouse calvariae in organ culture after 72 h of incubation. hPTHrP-(1-34) gave a dose-response between 0.2 and 5 ng/ml (5 X 10(-11) and 1.2 X 10(-9) M), was about 3 times more potent than Lilly bovine PTH standard (assuming a SA of 3000 U/mg; 100 U/ml), gave the same maximum response as hPTH-(1-34), and was 20-30% as potent as hPTH-(1-34). Neither hPTH-(1-34) nor hPTHrP-(1-34) enhanced prostaglandin production in mouse calvariae, and indomethacin did not inhibit the bone resorption-stimulating activities of either peptide. We conclude that hPTHrP-(1-34) and hPTH-(1-34) have similar high specific biological activities to stimulate production of cAMP in human osteoblast-like cells, but that hPTHrP-(1-34) is modestly less potent than hPTH-(1-34) to stimulate bone resorption in mouse calvariae.
人甲状旁腺激素相关蛋白(hPTHrP)已被鉴定为肿瘤细胞的产物,其序列与人甲状旁腺激素(hPTH)具有生物活性的氨基末端部分同源。我们测量了hPTH-(1-34)和hPTHrP-(1-34)的合成氨基末端序列在完整的人SaOS-2骨肉瘤细胞中刺激环磷酸腺苷(cAMP)产生的相对活性。两种肽在2.5 - 7.5×10(-10) M的浓度下均增强了cAMP的产生,具有平行的剂量反应曲线,且效力基本相等。将SaOS-2细胞与hPTH-(1-34)或hPTHrP-(1-34)预孵育1或4小时,可诱导对同一肽的第二次刺激产生同源脱敏以及对另一种PTH肽产生异源脱敏,但对血管活性肠肽的作用几乎没有影响;相同剂量的hPTHrP-(1-34)或hPTH-(1-34)诱导的同源和异源脱敏程度相似。在器官培养中孵育72小时后,使用新生小鼠颅骨释放40Ca2+来测量骨吸收刺激活性。hPTHrP-(1-34)在0.2至5 ng/ml(5×10(-11)至1.2×10(-9) M)之间呈现剂量反应,效力约为礼来牛PTH标准品(假设比活性为3000 U/mg;100 U/ml)的3倍,与hPTH-(1-34)产生相同的最大反应,且效力为hPTH-(1-34)的20 - 30%。hPTH-(1-34)和hPTHrP-(1-34)均未增强小鼠颅骨中前列腺素的产生,吲哚美辛也未抑制任何一种肽的骨吸收刺激活性。我们得出结论,hPTHrP-(1-34)和hPTH-(1-34)在刺激人成骨样细胞产生cAMP方面具有相似的高特异性生物活性,但hPTHrP-(1-34)在刺激小鼠颅骨骨吸收方面的效力略低于hPTH-(1-34)。